StageSeries A - II | Alive
Last Raised$54M | 1 yr ago
Mosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+20 points in the past 30 days
Missing: Engitix's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Engitix's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Engitix
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Engitix is included in 4 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Latest Engitix News
Mar 22, 2023
Global pharmaceutical company moves into life sciences hub White City Place invoX Pharma Ltd (invoX), a global biopharmaceutical company, has agreed to lease 2,500 sq ft as its headquarters in the WestWorks building at White City Place, part of the White City Innovation District with Imperial College London. invoX’s mission is to be a fully integrated biopharmaceutical company with an advancing pipeline of innovative products addressing unmet healthcare needs, worldwide. At its core, the Company aspires to improve patients’ lives by creating access to innovative medicine. invoX Pharma Ltd is a wholly-owned subsidiary of Sino Biopharmaceutical Limited, a global top 50 pharmaceutical company with more than 24,000 employees. invoX's international centre of excellence in antibody research and clinical development is based in Cambridge which is a part of the Golden Triangle with Oxford and London universities. Ben Toogood, CEO of invoX, said: “We are excited to be moving into the life sciences hub at White City Place with so many global and UK leading pharmaceutical and biotech companies like Novartis, Takeda, Autolus and Engitix as neighbours. invoX is well on its way, through multiple acquisitions and investments, to create a scalable platform to build a portfolio of promising clinical and pre-clinical stage drug candidates. We recently completed the acquisition of F-star therapeutics, a clinical-stage biopharmaceutical company pioneering bispecific antibodies in immunotherapy, accelerating the build of our pipeline. We believe these programs have the potential to improve people’s lives by creating access to innovative medicine across some of our key therapeutic areas including oncology and respiratory.” David Camp, CEO of Stanhope, said: “Together with our partner and owner of White City Place, Cadillac Fairview, we are delighted to welcome another innovative life sciences company to the WestWorks building. White City Place has rapidly become a leading life sciences hub and, as part of the White City Innovation District, is competing on the global stage at the cutting edge of sustainable development.” Stanhope and Cadillac Fairview have already attracted to White City Place numerous major life science occupiers, Novartis, Autolus, Takeda, Engitix, Synthace and Vivan Therapeutics, totalling over 130,000 sq ft. Stanhope and its partners Mitsui Fudosan and AIMCo are developing the Gateway development at White City Place with two buildings now complete, which is helping to transform White City into a global economic hotspot for STEM. Editor Details
Engitix Frequently Asked Questions (FAQ)
When was Engitix founded?
Engitix was founded in 2016.
Where is Engitix's headquarters?
Engitix's headquarters is located at 21 Lombard Street, London.
What is Engitix's latest funding round?
Engitix's latest funding round is Series A - II.
How much did Engitix raise?
Engitix raised a total of $60.37M.
Who are the investors of Engitix?
Investors of Engitix include Dompe Farmaceutici, Netherton Investments and University College London.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.